The main reasons for not intensifying antihypertensive treatment when BP remained above goal were the assumption that the time after starting the new drug was too short to attain its full effect, the satisfaction with a clear improvement of BP or with a BP nearing the goal, and the acceptance of good self-measurements. In this open intervention program in primary care, a large proportion of patients achieved recommended BP goals. The belief that a clear improvement in BP is acceptable and that the full drug effect may take up to several weeks to be reached are frequent reasons for treatment inertia when goals are not achieved.
Introduction
It has been shown that each increment in blood pressure (BP) of 20/10 mm Hg doubles the risk of cardiovascular disease across the entire BP range starting from values of 115/75 mm Hg.
1,2 New international hypertension guidelines recommend that the decision to start treatment should depend not only on the level of BP, but also on an assessment of the total cardiovascular risk and the presence of co-morbidities and dictate that the target BP to be achieved during therapy must be based on individual CV risk profile. 1, 2 Targets for some hypertensive patients with co-morbidities such as diabetes and kidney disease have been set lower than for hypertensive patients without these conditions. 1, 2 Consequently, improved recognition, diagnosis and treatment of hypertension rank among the top priorities in all healthcare systems.
Despite these recommendations and the increased knowledge of deleterious consequences of hypertension, there is still a substantial proportion of individuals in the general population with hypertension who remain unrecognized, with less than a quarter of the treated patients who have their BP treated to target. [3] [4] [5] The most frequent reasons cited for these disappointing results are the relative inefficacy of the antihypertensive treatments and the poor tolerability or the poor compliance leading to an early treatment discontinuation. 6, 7 An underrecognized problem is the failure of consensus guidelines to acknowledge the important difference between efficacy in clinical trials and effectiveness in clinical practice and the fact that clinicians have not fully accepted current guidelines recommendation of the treatment of hypertension or treating to achieve a goal BPo140/90 mm Hg. 8, 9 Another possible factor that has been labelled therapeutic inertia 10 is the failure of physicians to begin a new antihypertensive therapy or increased dosage of existing medications when high BP readings are documented.
There has been little recent research on physician beliefs and practices with regard to the treatment of hypertension in recent years (for a review see Ferrari et al. 11 ). Moreover, current international hypertension guidelines are largely based on information from epidemiological data or intervention trials, which is primarily based on patients from so-called industrialized countries, are of Caucasians and to a smaller degree African-American background, 1,2 and thus very little is known about prevalence, awareness, treatment and response to intervention in nonWestern countries. However, differences in ethnical and cultural characteristics in specific knowledge and beliefs about hypertension exist and may account for some of the disparities in BP control. 12 The lack of such data from non-Western countries prompted this international large-scale observational registry survey. This survey was conducted under the heading 'Reasons for not Intensifying Antihypertensive Treatment ' with the acronym RIAT, because one of the key questions addressed was to assess why antihypertensive treatment is not intensified when individual targets are not achieved. Results from a previous study with a similar design performed in Switzerland have been published elsewhere. 5 The RIAT survey is an observational study of unselected patients mainly attending primary care settings, recruited from a representative sample of medical practitioners in 16 countries in Latin America, Eastern Europe, Africa and Asia. 11 
Methods
The detailed study design, sampling of medical practitioners, instruments and measures and diagnostic conventions used in RIAT were previously presented elsewhere. 11 Briefly, in RIAT step 3, physicians prospectively collected patients' data relevant to assess CV risk profile at baseline, they were asked to determine individual BP values as the target to reach for the next visits and to initiate or optimise antihypertensive treatment. Hypertensive patients were enrolled after a baseline visit if they were either treated, but with BP higher than recommended targets, or previously untreated. Thereafter, up to three follow-up visits were allowed to monitor the achievement of these target values (Figure 1) . If the BP goal was not achieved physicians were free to up-titrate or add new medications to achieve blood pressure control. The primary objectives of this step were to identify what is the BP targeted by physicians according to existing associated risk factors and to evaluate what are the reasons for not modifying/adapting an antihypertensive treatment whereas individual BP targeted figures have not been reached.
Hypertension was classified in accordance with the definition adopted by NHANES, 13 which defines hypertension as measured BP X140/90 mm Hg or receiving antihypertensive therapy, irrespective of the doctor's or patient's self-reported diagnosis. Patients gave informed consent for collection of their data. A standardized subject-informed consent was submitted to the local ethics committees for approval in compliance with local policies. Recruitment commenced in January 2004 and the database was closed in October 2006.
Statistical analyses
Statistical analysis was based on all patients enrolled in the registry. Data is summarized using mean, median, s.d. and range for continuous parameters and counts and percentages for categorical parameters. As this is a descriptive registry, no sample size calculation was applied. The relative and the absolute differences between the target value and the value at the visit were computed. Differences between the visits and the baseline, between the target value and the value at each visit were compared with Student's test or Wilcoxon test for paired data. As physicians were asked an openended question to report the reasons for not changing the treatment, a list of possible pre-defined answers was defined for use in the statistical 
Results
In the 16 countries, 1596 centres participated in the study and recruited 35 302 patients, of these 32 224 (91.3%) completed follow-up visit 4 ( Figure 1 ). The mean interval between each visit was approximately 1 month ( Figure 1 ). There were 22 887 treated hypertensive patients whose BP was higher than recommended targets and 12 250 previously untreated hypertensive subjects (165 missing data). Among untreated patients, 10 166 (83%) were newly diagnosed patients. The overall disposition of patients by country is presented in Table 1 . Korea and Taiwan recruited 76.6% of all patients. There were 747 patients with at least one minor protocol deviation (normalization of BP, N ¼ 733; o18 years old N ¼ 8; age missing, N ¼ 6) and 2287 patients who did not complete the study (lost to follow-up, N ¼ 1948; one or more other reasons, N ¼ 444). Baseline characteristics of patients who did not complete the survey did not differ to those who did complete the study.
The population comprised 17 722 men (50.2%) and 17 565 women (49.8%). Mean age was 59 ± 13 years. The population had a mean height of 163±9 cm, a mean weight of 67±12 kg and a mean BMI of 25 Defining the target Most physicians defined a target for their patients identical or lower than the one specified by national or international guidelines. Ten countries followed JNC VII hypertension guidelines 1 and two of them (Indonesia and Saudi Arabia) indicated that they also used WHO/ISH guidelines. 2 Management of hypertension in general practice was guided by National guidelines in six countries (China, Korea, Lebanon, Malaysia, Russia and Singapore). An Reasons for not modifying an antihypertensive drug regimen Figure 2 shows the decision tree of the physicians in relation to whether BP targets set at baseline were reached or not at the follow-up visits. There were six main reasons reported to justify maintaining an unchanged drug treatment despite higher than desired BP values. These were: awaiting full drug effect or time to short; target almost reached or clear improvement; poor compliance; reduction of other risk factors; side effects; and good self-measurements or white-coat hypertension. An additional group labelled as 'other reasons' included drug discontinuation for other reasons; other concurrent illness (for example, drug substitution, dose modification); costs and unclassified (for example, unknown, illegible, drug substitution in formulary). The main reasons for not changing the antihypertensive therapy at each visit for patients who did not achieve the target BP are listed in Figure 3 .
At the first follow up visit (visit 2), the assumption that the time after starting the new drug was too short to appreciate its full effect was the leading cause of unchanged treatment (85%). The argument that there was a clear improvement in BP control or that the target BP was almost reached accounted for 3% of cases at the first follow-up visit. At the last visit the main reason to leave the therapy unchanged despite unmet target BP remained the belief that the interval after starting the new drug was too short to appreciate its full effect (34%), whereas a clear improvement in BP control or a target BP that was almost reached was considered acceptable in 20% of cases and good self-measurements or white-coat hypertension were reported as a good motive not to change the antihypertensive regimen in 16% of cases. Issues on the compliance of the patients and modification of other risk factors (for example, smoking, lipid disorders, overweight) accounted for approximately 4% each of the reasons for not intensifying antihypertensive treatment throughout the study (Figure 3 ).
Achieving the target
At baseline BP averaged 159±15 mm Hg for systolic and 95±12 mm Hg for diastolic and the last visit these figures averaged 132 ± 11 mm Hg and 81 ± 8 mm Hg, respectively (Po0.0001 vs baseline, Figure 4 ). BP targets were more likely to be achieved in non-diabetic than diabetic patients (88.4 vs 71.2%, Po0.005) and in previously untreated patients compared with those who were already on antihypertensive drugs at baseline (92 vs 80.1%, Figure 2 Decision tree of the physicians in relation to whether blood pressure (BP) goals set at baseline were reached or not at follow-up visits.
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Po0.05). Therapeutic inertia in hypertension P Ferrari than the target in 6% of patients at the first and 4% at the last follow-up visit. In nearly 99% of patients at any follow-up visit whose target BP was considered not reached by the physician, measured BP values were higher than the set target. Previously untreated patients were more likely to be treated with monotherapy than those who were already on antihypertensive drugs at baseline (Po0.0001). The average number of antihypertensive agents in previously untreated patients was 1.17, whereas patients who were on antihypertensive drugs at baseline and whose BP was uncontrolled received an average of 1.67 agents. Of patients treated with three or more drugs 63% were on a 3-drug regimen including a diuretic.
Change of antihypertensive medication when target is reached
When target BP was achieved according to the physician, a change in therapy was rarely undertaken (5.2 and 2.1% at first and last visit respectively). At the three follow-up visits 1956 patients had their antihypertensive treatment modified despite achieving targets because of side effects from the prescribed medication (31%) or because achieved BP exceeded targets (28%), with other reasons reported in 16% of the patients.
Discussion
The current study demonstrates a few striking findings that are relevant to everyday clinical practice and may provide useful information to help overcome barriers in the management of hypertension. First, in participating countries physicians' knowledge of hypertension guidelines is excellent. Second, physicians define lower BP targets for patients with diabetes or renal disease as recommended by guidelines. Third, physicians often fail to intensify antihypertensive therapy when BP goals are not achieved. Fourth, frequent follow-ups lead to a high rate of patients achieving BP targets, even if the treatment is not intensified.
Fifth, a simple intervention that raises the awareness of hypertension guidelines in clinical practice enables achieving high BP control rates.
Although the focus is on non-Western countries we did not compare the information with regard to BP control success in these countries versus Western countries and therefore it is not possible to come to a conclusion whether this data represents better, worse or similar practice to Western countries.
Hypertension affects over 30% of adults in the United States. 1 Based on randomized control trials the BP control rates can be substantially improved up to 70%. [14] [15] [16] However, only 53% of hypertensive patients on therapy achieve BP control rates o140/ 90 mm Hg based on the National Health and Nutrition Examination Survey, with little improvement over the last 15 years. 1, 4 Many factors contribute to poor BP control, including failure of patients to attend physicians, failure of physicians to detect and adequately treat hypertension to goal levels, and failure of patients to persist with prescribed therapy. Failure of physicians to intensify antihypertensive therapy when BP goals are not achieved has been described as therapeutic inertia and has been shown to represent a significant barrier to improved hypertension control in a retrospective observational database analysis. 10 Strictly speaking the term therapeutic inertia should be reserved for physicians who have knowledge of the guidelines but do not apply them. However, in the analysis of Okonofua 10 this was not assessed. Moreover, there was no distinction between visits specific for the management of hypertension and visits for other medical reasons when BP was also recorded and this may lead to an over-interpretation of therapeutic inertia. This study demonstrates that practitioners in many countries of different background have a good knowledge of hypertension guidelines and that they aim at lower BP goals in diabetic patients and also in those with other cardiovascular risk factors. Importantly, a BP goal X5 mm Hg above the target mandated by guidelines was aimed by physicians in o4% of their patients. This compares favourably with previous reports. 8, 17 In the United States, many physicians have been reported to apply BP The number of patients at visit 3 is superior to that of visit 2 on account of the fact that some patients do not attend visit 2.
b
Percentage of those not reaching BP goals.
Therapeutic inertia in hypertension P Ferrari thresholds for the diagnosis and treatment of hypertension 8 higher than the 140/90 mm Hg criterion recommended by the JNC. 3 Another study showed that sufficient knowledge of hypertension guidelines was found in only 37% of cardiologists and 19% of general practitioners. 17 In this study, over 60% of patients who did not achieve BP targets at any given follow-up visit had their antihypertensive medication unchanged. Physicians justify this high degree of therapeutic inertia with the assumption that the time for the drug to show the full effect is too short or that a clear improvement is acceptable. This attitude seems to support Okonofua's hypothesis 10 and has been reported by others. 5, 10, 18 It is interesting to observe that approximately 10 000 patients whose BP was not on target and whose antihypertensive treatment was not changed at visit 3 achieved BP goals at visit 4. There may be a few reasons for this apparent paradox observation. First, repeated consultations that specifically aim at treating hypertension may improve patients' adherence to the prescribed treatment when visits occur within a relatively short time. 19, 20 Second, a placebo effect could have a function. Response rates for placebo in mild to moderate hypertension are high, but not necessarily rapid and responder rates of around 30% have been described during a follow-up period of up to 12 months. 21 Third, one of the errors in BP measurements is the so-called end-digit preference which corresponds to the rounding up to a 5 or 10 mm Hg of measured readings. 22, 23 Indeed, a clear numerical preference was found when the systolic and diastolic BP was expressed in multiples of 5 in 11% and in multiples of 10 in 51% of cases, so that when a cutoff point o140/90 mm Hg is chosen in daily practice, 130/85 mm Hg is actually being selected. In our trial, because of the end-digit preference significantly more patients had controlled hypertension when p140/90 mm Hg was applied (N ¼ 29 598, 84%) than when o140/90 mm Hg was used (N ¼ 22 631, 70%) to define BP control. The use of multiple measures has been shown to reduce this effect and policy makers and guideline authors should consider these aspects when setting BP goals. 24, 25 The higher rate of diabetic patients not reaching the target BP is partly because of BP goals for this group being 10 mm Hg lower than in nondiabetic subjects and partly to a greater difficulty in managing hypertension in diabetes.
There are some limitations to the present survey. First of all, this survey was not a population-based survey in any of the participating countries, so the findings are unlikely to be representative for the general population. Second, two countries recruited 3 4 of the patients in this survey, although a separate analysis of the key findings presented herein excluding data from these two countries yielded similar results (data not shown). Third, four visits within 4 months to specifically manage hypertension do not reflect a real-life scenario in many primary care settings. Thus, the results, in particular those related to the high BP control rate, may be difficult to reconcile at a larger scale. Fourth, there was no recommended pre-specified strategy to intensify antihypertensive treatment. This may have actually reduced the chance of a better response, given that in patients receiving two antihypertensive agents only 26% were prescribed a diuretic.
Consensus guidelines are based on efficacy data obtained in clinical trials with strict protocols, but effectiveness in clinical practice, particularly in terms of responder rate, may not be readily reproduced. Our data demonstrates that medical practitioners have a good knowledge of current hypertension guidelines that recommend targeting individual BP goals based on cardiovascular risk stratification. This is in contrast to a previous study that found that among medical practitioners BP goals for hypertensive patients were not tailored on individual risk stratification. 5 Cranney et al. 24 identified several barriers to the implementation of evidence-based guidelines in the management of hypertension, including doubts about the applicability of trial data to particular patients, poor adherence of practice protocols and absence of an effective computer system or an educational mentor. Our findings suggest that a simple protocol may improve adherence to a practice protocol while serving as an educational tool. However, many physicians feel that hypertension is not a priority, often because of lack of time or administrative burdens, or because of the growing number of important clinical areas. 24 Depending on the funding model, a specific reimbursement item for the management of hypertension that rewards physicians who apply treatment goals, possibly in conjunction with assisted management by a practice nurse or a pharmacist could result in improved achievements of treatment targets. 26, 27 What is known about this topic:
K There are still a substantial proportion of patients with hypertension who do not have their blood pressure controlled. K Failure of physicians to adhere to hypertension guidelines partly accounts for the failure to achieve blood pressure goals in clinical practice. K Physicians' attitudes in the management of hypertension differ among various countries of dissimilar cultural or ethnic background.
What this Study adds:
K The reasons why physicians fail to achieve blood pressure goals in non-Western countries are similar to those previously reported in studies from the US and Europe. K The belief that a clear improvement in BP is acceptable and that the full drug effect may take up to several weeks to be reached are frequent reasons for not intensifying antihypertensive treatment when targets are not achieved. K When primary care physicians are asked to specifically focus on the management of hypertension in an open intervention program a large proportion of patients achieve recommended BP goals.
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